THE WOODLANDS, Texas, Sept. 13, 2011 /PRNewswire/ — Lexicon Pharmaceuticals, Inc.
(Nasdaq:
LXRX), a biopharmaceutical company focused on discovering
breakthrough treatments for human disease, reported positive data
from a recently completed clinical trial and mechanistic study of
LX4211, a dual inhibitor of the sodium glucose transporters 1 and 2
(SGLT1 and SGLT2). The favorable safety profile and effects
on multiple parameters of glycemic control and cardiovascular
health in healthy normal subjects support the broad potential of
LX4211 in the treatment of diabetes and associated metabolic
conditions.
“Newly observed in this study were the effects of LX4211, in
healthy volunteers, of decreasing postprandial glucose levels
without hypoglycemia and substantially reducing triglycerides,”
said Brian Zambrowicz,
Ph.D., executive vice president and chief scientific officer.
“Notably, the magnitudes of the reductions in triglycerides
were similar to current standard of care prescription and
clinical-stage medicines. By contrast, reported results of
SGLT2-selective compounds have demonstrated minimal or no
reductions in postprandial glucose in healthy subjects and minimal
or no triglyceride decreases in either healthy normal volunteers or
patients with type 2 diabetes.”
Results from the study demonstrated that the 400 mg solid oral
dose of LX4211 compared to placebo significantly reduced mean
changes from baseline in fasting plasma glucose (p=0.005) and
post-prandial glucose levels (p<0.001) in parallel with
meaningful mean increases from baseline in total and active GLP-1
(p=0.055 and p=0.003, respectively) as well as PYY (p<0.001).
GLP-1 is associated with improved glucose control and
decreased food intake through reduction of appetite. PYY is a
gas
‘/>”/>
